Michael Cichowlas, DO
Family Medicine · Sterling Heights, MINPI 1922014091
Payments from drug & device makers
Across 201 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$904
- Amgen$524
- Pfizer$185
- GSK$169
- Boehringer Ingelheim$169
- Johnson & Johnson$150
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,230100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 73 | $904 |
| Amgen(2 entities) | 30 | $524 |
| Pfizer | 12 | $185 |
| GSK | 11 | $169 |
| Boehringer Ingelheim | 8 | $169 |
| Johnson & Johnson | 9 | $150 |
| Amarin Pharma, Inc. | 9 | $141 |
| SPR Therapeutics, Inc | 1 | $135 |
| Lilly USA, LLC | 9 | $132 |
| Esperion Therapeutics, Inc. | 7 | $100 |
| Intra-sana Laboratories | 3 | $99 |
| Novartis | 6 | $90 |
| Exact Sciences | 3 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Dexcom, Inc. | 2 | $46 |
| Merck | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Rhythm Pharmaceuticals, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,230 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 125 | $132,977 |
| OzempicSemaglutide | 51 | $70,874 |
| JanuviaSitagliptin Phosphate | 60 | $61,661 |
| XareltoRivaroxaban | 46 | $55,907 |
| TrulicityDulaglutide | 32 | $48,337 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $46,549 |
| JardianceEmpagliflozin | 35 | $44,663 |
| MounjaroTirzepatide | 24 | $28,677 |
| CreonLipase/Protease/Amylase | 11 | $25,161 |
| Spiriva RespimatTiotropium Bromide | 18 | $19,002 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $16,794 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $13,596 |
| Telmisartan | 271 | $11,153 |
| Atorvastatin Calcium | 752 | $10,531 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $10,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $185 | $135,698144 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $132 | $77,01456 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $169 | $73,56573 claims |
| Novo NordiskOzempic | $904 | $70,87451 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $169 | $63,66553 claims |
| MerckJanuvia | $38 | $61,66160 claims |
| Johnson & JohnsonXarelto | $150 | $55,90746 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Sterling Heights
- Jeffrey DeitchSterling Heights$220K
- Stuart StollerSterling Heights$141K
- Steven MargolisSterling Heights$91K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.